Elutia Inc. secures deal with Advantus Health Partners

SILVER SPRING, Md. - Elutia Inc. (NASDAQ:ELUT), a developer of drug-eluting biomatrix products with a market capitalization of approximately $108 million, has announced a new agreement with Advantus Health Partners to include its EluPro™ Antibiotic Eluting BioEnvelope in Advantus’s group purchasing organization (GPO) portfolio. This marks the seventh such GPO agreement for Elutia since the product’s launch. According to InvestingPro data, the stock appears undervalued based on its Fair Value analysis, despite falling nearly 20% in the past week.

EluPro, which is the first and only FDA-cleared antibiotic-eluting biologic envelope for use with cardiac implantable electronic devices (CIEDs) and neurostimulators, aims to prevent post-surgical infections and other complications. Dr. Kimberly Mulligan, GM and VP of Elutia’s Cardiovascular Division, expressed satisfaction with the product’s pilot launch and anticipates that the partnership with Advantus will expand EluPro’s availability to physicians across the nation.

Advantus Health Partners specializes in supply chain management and cost-savings efficiencies in healthcare, striving to reduce healthcare costs in the U.S. The company’s collaboration with Elutia is expected to support its mission through the integration of EluPro into its contracting solutions.

Elutia’s focus is on humanizing medicine by developing products that enhance compatibility between medical devices and patients. The company emphasizes innovation in its efforts to meet the needs of a growing population requiring implantable technologies.

The press release also contains forward-looking statements regarding the anticipated success of EluPro in the market, including its potential to become a transformative solution for patients and clinicians. However, the company acknowledges the risks and uncertainties inherent in such projections, which include but are not limited to the ability to successfully commercialize and market EluPro. InvestingPro analysis reveals that analysts do not expect profitability this year, with forecasted EPS of -$0.88. Subscribers can access 7 additional ProTips and comprehensive financial metrics in the Pro Research Report, providing deeper insights into Elutia’s financial health and growth prospects.

The information for this article is based on a press release statement from Elutia Inc. and does not include any promotional content or subjective assessments. It provides a factual overview of the new agreement between Elutia Inc. and Advantus Health Partners, the potential benefits of EluPro, and the company’s mission and product development focus.

In other recent news, Aziyo Biologics Inc. reported a year-over-year revenue decline of approximately 7% for the fourth quarter of 2024, totaling $5.5 million. This result met the FactSet consensus but was below Cantor Fitzgerald’s expectation of $6.3 million. The decrease in revenue was largely due to a 23% drop in SimpliDerm sales, while BioEnvelope products experienced an 18% increase, driven by strong initial sales of EluPro. Cardiovascular products saw a 20% decline, with sales reaching $0.5 million. Despite these mixed results, Cantor Fitzgerald maintained an Overweight rating on Aziyo’s stock with an $8.00 price target, expressing optimism for the company’s future growth, particularly with the involvement of Boston Scientific in EluPro sales. Meanwhile, Elutia Inc. also reported a 7% revenue decline for the same quarter, posting $5.47 million in revenue and missing the anticipated $6.3 million. Elutia’s earnings per share were -$0.26, falling short of the forecasted -$0.24. Positive developments for Elutia included the launch of EleuPro and a partnership with Boston Scientific, which are expected to support future growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.